- Albertsons to acquire Safeway in deal worth more than $9.1 billion to Safeway shareholders
- Safeway confirms grocer is exploring possible sale
- Safeway receives FTC request for additional information
- Safeway, Albertsons merger proceeds to next step as 'go-shop' period expires
- Senate passes Drug Quality and Security Act
PLEASANTON, Calif. — Safeway on Friday announced that its stores raised $10.3 million during the company's annual Prostate Cancer Awareness campaign.
For the 13th consecutive year, Safeway's entire chain of more than 1,600 stores dedicated a month to raising money and increasing awareness for the fight against prostate cancer, which currently affects more than two million American men and remains the second-leading cause of cancer death for men in the United States.
"We'd like to express our gratitude to our customers who have, year after year, shown commitment to this important cause by contributing and helping to save lives, one dollar at a time," stated Larree Renda, Safeway EVP and chair of the Safeway Foundation.
To date, Safeway's customers have donated nearly $86.8 million to the cause.
To identify the most promising and groundbreaking prostate cancer research projects for funding, Safeway and The Safeway Foundation have partnered with a range of cancer research organizations, such as the Prostate Cancer Foundation, Stand Up to Cancer and the University of California at San Francisco. The donations have funded more than 1,600 research projects.
Over the past three years, six new prostate cancer drugs were approved by the Food and Drug Administration and dozens of new drugs are currently in trials due to Safeway's support, the grocer stated. Safeway's support has also led to a treatment that may decrease cancer deaths by 20% per year by deploying new combinations of surgery and medications early in the course of the disease.
A new advancement in early detection that was funded by Safeway and Safeway Foundation is a simple test to detect a unique piece of DNA found only in prostate cancer cells. The test gives doctors the potential to catch prostate cancer many years earlier. When used with a standard Prostate-Specific Antigen test and a checkup, doctors can not only accurately determine if a patient has prostate cancer, but can also predict how aggressive the cancer might be, and potentially avoid biopsies and such radical treatments as chemotherapy, radiation and surgery.